Important breakthroughs in medical treatments have improved outcomes for patients suffering from several types of cancer. However, many oncological treatments approved by regulatory agencies are of low value and do not contribute significantly to cancer mortality reduction, but lead to unrealistic patient expectations and push even affluent societies to unsustainable health care costs. Several factors that contribute to approvals of low-value oncology treatments are addressed, including issues with clinical trials, bias in reporting, regulatory agency shortcomings and drug pricing. With the COVID-19 pandemic enforcing the elimination of low-value interventions in all fields of medicine, efforts should urgently be made by all involved in cancer care to select only high-value and sustainable interventions. Transformation of medical education, improvement in clinical trial design, quality, conduct and reporting, strict adherence to scientific norms by regulatory agencies and use of value-based scales can all contribute to raising the bar for oncology drug approvals and influence drug pricing and availability.

医学治疗方面的重大突破改善了患有多种癌症的患者的预后。然而，监管机构批准的许多肿瘤治疗价值低，对降低癌症死亡率没有显着贡献，反而会导致不切实际的患者期望，甚至将富裕社会推向不可持续的医疗保健成本。解决了有助于批准低价值肿瘤治疗的几个因素，包括临床试验问题、报告偏差、监管机构缺陷和药物定价。随着 COVID-19 大流行强制消除所有医学领域的低价值干预措施，所有参与癌症治疗的人都应紧急努力，只选择高价值和可持续的干预措施。医学教育转型，